{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:24:34Z","timestamp":1792571074770,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.4158\/ep161309.ra","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T14:46:50Z","timestamp":1481726810000},"page":"363-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Impact of Cardiovascular Drugs on Glycemic Control: A Review"],"prefix":"10.1016","volume":"23","author":[{"given":"Anna","family":"Grodzinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne V.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Draznin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP161309.RA_bb0010","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2013.02.044","article-title":"Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status","volume":"61","author":"Amin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161309.RA_bb0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ahj.2014.06.023","article-title":"Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction","volume":"168","author":"Arnold","year":"2014","journal-title":"Am Heart J"},{"key":"10.4158\/EP161309.RA_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/diaclin.22.4.162","article-title":"Effects of glycemic control on diabetes complications and on the prevention of diabetes","volume":"22","author":"Skyler","year":"2004","journal-title":"Clin Diabetes"},{"key":"10.4158\/EP161309.RA_bb0025","doi-asserted-by":"crossref","unstructured":"RayKK, SeshasaiSRK, WijesuriyaS, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 373:1765\u20131772.","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"10.4158\/EP161309.RA_bb0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2337\/diacare.23.7.934","article-title":"Depression and poor glycemic control: a meta-analytic review of the literature","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP161309.RA_bb0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.clinthera.2006.08.006","article-title":"Clinically important drug-disease interactions and their prevalence in older adults","volume":"28","author":"Lindblad","year":"2006","journal-title":"Clin Ther"},{"key":"10.4158\/EP161309.RA_bb0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro","year":"2011","journal-title":"Circulation"},{"key":"10.4158\/EP161309.RA_bb0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-0002-3","article-title":"Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"45","author":"Tang","year":"2014","journal-title":"Endocrine"},{"key":"10.4158\/EP161309.RA_bb0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejphar.2013.03.016","article-title":"Cilostazol ameliorates systemic insulin resistance in diabetic db\/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions","volume":"707","author":"Wada","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.4158\/EP161309.RA_bb0055","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1161\/01.CIR.0000070983.15903.A2","article-title":"Beta-Adrenergic Blockers","volume":"107","author":"Frishman","year":"2003","journal-title":"Circulation"},{"key":"10.4158\/EP161309.RA_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.eurheartj.a059591","article-title":"Diabetic patients and beta-blockers after acute myocardial infarction","volume":"11","author":"Kjekshus","year":"1990","journal-title":"Eur Heart J"},{"key":"10.4158\/EP161309.RA_bb0065","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.4158\/EP161309.RA_bb0070","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1089\/ars.2007.2013","article-title":"Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities","volume":"10","author":"Le Brocq","year":"2008","journal-title":"Antiox Redox Signal"},{"key":"10.4158\/EP161309.RA_bb0075","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","article-title":"Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: A randomized, controlled trial","volume":"126","author":"Giugliano","year":"1997","journal-title":"Ann Inter Med"},{"key":"10.4158\/EP161309.RA_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00547413","article-title":"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension","volume":"29","author":"Ohman","year":"1985","journal-title":"EUr J Clin Pharmacol"},{"key":"10.4158\/EP161309.RA_bb0085","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"10.4158\/EP161309.RA_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2840-9-21","article-title":"Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes-a randomized study","volume":"9","author":"Kveiborg","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP161309.RA_bb0095","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.amjcard.2012.11.031","article-title":"Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol)","volume":"111","author":"DiNicolantonio","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP161309.RA_bb0100","doi-asserted-by":"crossref","unstructured":"ArnoldSV, SpertusJA, LipskaKJ, et al. Type of b-blocker use among patients with versus without diabetes after myocardial infarction. Am Heart J. 168:273\u2013279.","DOI":"10.1016\/j.ahj.2014.04.018"},{"key":"10.4158\/EP161309.RA_bb0105","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/HYPERTENSIONAHA.111.184226","article-title":"Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study","volume":"59","author":"Muramatsu","year":"2012","journal-title":"Hypertension"},{"key":"10.4158\/EP161309.RA_bb0110","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney Int"},{"key":"10.4158\/EP161309.RA_bb0115","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"issue":"Suppl 4","key":"10.4158\/EP161309.RA_bb0120","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1136\/hrt.2005.078790","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"10.4158\/EP161309.RA_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"10.4158\/EP161309.RA_bb0130","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.4158\/EP161309.RA_bb0135","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP161309.RA_bb0140","first-page":"A234","article-title":"Inhibition of glucagon secretion in rat pancreatic islets via Na+ channels: mechanism of anti-diabetic effect of ranolazine","volume":"62","author":"Yang","year":"2013","journal-title":"Diabetes"},{"key":"10.4158\/EP161309.RA_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/pgmj.75.879.27","article-title":"Evolution of insulin resistance in coronary artery disease patients on four different pharmacological therapies","volume":"75","author":"Pi\u00e9drola","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.4158\/EP161309.RA_bb0150","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1440-1681.2009.05195.x","article-title":"Oral nitrate therapy does not affect glucose metabolism in healthy men","volume":"36","author":"Henstridge","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.4158\/EP161309.RA_bb0155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.4158\/EP161309.RA_bb0160","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","article-title":"Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction","volume":"62","author":"Arnold","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161309.RA_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2012.06.001","article-title":"Statins are diabetogenic \u2013 Myth or reality?","volume":"13","author":"Sattar","year":"2012","journal-title":"Atheroscler Suppl"},{"issue":"Suppl 1","key":"10.4158\/EP161309.RA_bb0170","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1475-2840-12-S1-S3","article-title":"Statin diabetogenicity: guidance for clinicians","volume":"12","author":"Ray","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP161309.RA_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.4158\/EP161309.RA_bb0180","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2337\/dc13-2215","article-title":"Statins and the risk of diabetes: evidence from a large population-based cohort study","volume":"37","author":"Corrao","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.4158\/EP161309.RA_bb0185","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1475-2840-12-S1-S2","article-title":"Pitavastatin in cardiometabolic disease: therapeutic profile","volume":"12","author":"Masana","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.4158\/EP161309.RA_bb0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.4158\/EP161309.RA_bb0195","unstructured":"HounslowNPR, SuzukiM, BettingP, GiralP, ChapmanMJ.Pitavastatin is without effect on glycaemic parameters in metabolic syndrome (CAPITAIN Study) [abstract]In: Program of the World Congress of Diabetes, November 11\u201314, 2012; Madrid, Spain. Abstract"},{"key":"10.4158\/EP161309.RA_bb0200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161309.RA_bb0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/EP161309.RA_bb0210","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161309.RA_bb0215","doi-asserted-by":"crossref","unstructured":"RajannaV, CampbellKB, LeimbergerJ, MohantyBD, GuytonJR.Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. J Clin Lipidol. 6:168\u2013173.","DOI":"10.1016\/j.jacl.2011.12.008"},{"key":"10.4158\/EP161309.RA_bb0220","doi-asserted-by":"crossref","first-page":"16B","DOI":"10.1016\/0002-9149(90)90436-5","article-title":"Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus","volume":"66","author":"Goldberg","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP161309.RA_bb0225","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0149-2918(95)80018-2","article-title":"Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus","volume":"17","author":"Sweany","year":"1995","journal-title":"Clin Ther"},{"key":"10.4158\/EP161309.RA_bb0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2337\/diacare.23.9.1407","article-title":"Fish oil supplementation in type 2 diabetes: a quantitative systematic review","volume":"23","author":"Montori","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP161309.RA_bb0235","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMe0803375","article-title":"Aliskiren and dual therapy in type 2 diabetes mellitus","volume":"358","author":"Ingelfinger","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161309.RA_bb0240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP161309.RA_bb0245","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"AVOID Study Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161309.RA_bb0250","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161309.RA_bb0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0021-5198(19)40038-3","article-title":"Effects of calcium channel blockers and hydralazine on plasma glucose levels in streptozotocin-induced diabetic rats in vivo","volume":"52","author":"Sunaga","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.4158\/EP161309.RA_bb0260","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/diab.29.3.193","article-title":"Mode of action of clonidine upon islet function: dissociated effects upon the time course and magnitude of insulin release","volume":"29","author":"Leclercq-Meyer","year":"1980","journal-title":"Diabetes"},{"key":"10.4158\/EP161309.RA_bb0265","doi-asserted-by":"crossref","first-page":"150S","DOI":"10.1016\/0895-7061(96)00290-7","article-title":"Hyperinsulinemia, insulin resistance, and the treatment of hypertension","volume":"9","author":"Lithell","year":"1996","journal-title":"Am J Hypertens"},{"issue":"Suppl 2","key":"10.4158\/EP161309.RA_bb0270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/dmrr.2355","article-title":"What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels?","volume":"28","author":"Standl","year":"2012","journal-title":"Pro and Cons. Diabetes Metab Res Rev"},{"key":"10.4158\/EP161309.RA_bb0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","article-title":"Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes","volume":"95","author":"Kostis","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.4158\/EP161309.RA_bb0280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diacare.27.1.247","article-title":"Antihypertensive therapy and incidence of type 2 diabetes: a systematic review","volume":"27","author":"Padwal","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/EP161309.RA_bb0285","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch Int Med"},{"key":"10.4158\/EP161309.RA_bb0290","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.4158\/EP161309.RA_bb0295","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.4158\/EP161309.RA_bb0300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4158\/EP161309.RA_bb0305","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.4158\/EP161309.RA_bb0310","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.4158\/EP161309.RA_bb0315","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.4158\/EP161309.RA_bb0320","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/EP161309.RA_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/blo.9.2.17.20","article-title":"Results of the STOP-Hypertension-2 trial","volume":"2","author":"Hansson","year":"2000","journal-title":"Blood Press Suppl"},{"issue":"Suppl 1","key":"10.4158\/EP161309.RA_bb0330","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1681\/ASN.2004110968","article-title":"Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses","volume":"16","author":"Chiurchiu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.4158\/EP161309.RA_bb0335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Int Med"},{"key":"10.4158\/EP161309.RA_bb0340","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1210\/jc.2006-0736","article-title":"Insulin sensitivity in patients with primary aldosteronism: a follow-up study","volume":"91","author":"Catena","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP161309.RA_bb0345","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"10.4158\/EP161309.RA_bb0350","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"10.4158\/EP161309.RA_bb0355","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"5","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"10.4158\/EP161309.RA_bb0360","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.4158\/EP161309.RA_bb0365","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.4158\/EP161309.RA_bb0370","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.4158\/EP161309.RA_bb0375","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/EP161309.RA_bb0380","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.4158\/EP161309.RA_bb0385","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic Strategies in Patients with Acute Decompensated Heart Failure","volume":"364","author":"Felker","year":"2011","journal-title":"New Engl J Med"},{"key":"10.4158\/EP161309.RA_bb0390","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00228-004-0727-2","article-title":"Drug use and increased HbA1c levels in non-diabetic very elderly persons: the Kungsholmen project","volume":"60","author":"Passare","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.4158\/EP161309.RA_bb0395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diabres.2016.01.021","article-title":"Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study","volume":"115","author":"Khodneva","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.4158\/EP161309.RA_bb0400","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13340-011-0032-0","article-title":"Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients","volume":"2","author":"Yamazaki","year":"2011","journal-title":"Diabetol Int"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20358213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:03:49Z","timestamp":1761516229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20358213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1530891X20358213"],"URL":"https:\/\/doi.org\/10.4158\/ep161309.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Cardiovascular Drugs on Glycemic Control: A Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP161309.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}